Published on 25 May 2023 on Simply Wall St. via Yahoo Finance
Cara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The Mark
You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. (NASDAQ:CARA) is a stock to potentially avoid, seeing as almost half of all the Pharmaceuticals companies in the United States have P/S ratios under 3.1x and even P/S lower than 0.9x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the elevated P/S.
View our latest analysis for Cara Therapeutics
